U.S. patent issued for use of oral estriol candidateTrimesta

[MSUK]

U.S. patent issued for Use of oral estriol candidate, Trimesta™, for Multiple Sclerosis

Synthetic Biologics Inc. has announced that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8658627 entitled Pregnancy Hormone Combination for Treatment of Autoimmune Diseases to the Regents of the University of California (UCLA). The patent includes claims to the use of the Company's drug candidate Trimesta™ (oral estriol) in conjunction with a gestagen for the treatment of multiple sclerosis (MS) and other autoimmune diseases. The patent also includes a claim for the administration of Trimesta™ a gestagen and a third standard of care MS agent such as glatiramer acetate injection (Copaxone®) interferon beta-1a (Avonex® Rebif®) interferon beta-1b (Betaseron® Extavia®) or sphingosine-1-phosphate receptor modulator (Gilenya®). Through its wholly owned subsidiary Synthetic Biologics holds the exclusive license to the newly issued U.S. Patent 8658627 as well as U.S. Patents 8372826 and 6936599 and pending patents for MS and other autoimmune diseases covering the uses of its oral estriol candidate Trimesta™.... Read More - http://www.ms-uk.org/trimesta